Pharm

Golimumab

search

Golimumab, Simponi

  • Contraindications
  1. See Tumor Necrosis Factor Inhibitor
  2. Not approved for use in children
  • Dosing
  1. See Monoclonal Antibody for preparation for use
  2. Background
    1. Injection sites include thigh, Abdomen and outer upper arm (rotate injection sites)
    2. Available as a Preloaded syringe or autoinjector
    3. Refrigerate and protect from light
    4. Allow to warm to room Temperature for 15 to 30 minutes before injection (decreased pain)
  3. Ulcerative Colitis
    1. Start: 200 mg SQ week 0
    2. Next: 100 mg SQ week 2
    3. Next: 100 mg SQ every 4 weeks
  4. Rheumatoid Arthritis, Psoriatic Arthritis, Akylosing Spondylitis
    1. SQ
      1. Maintenance: 50 mg SQ every month
    2. IV
      1. Induction: Infuse 2 mg/kg IV over 30 minutes at week 0 and 4 weeks
      2. Maintenance: Infuse 2 mg/kg IV over 30 minutes every 8 weeks
  • Precautions
  1. See TNF Inhibitor
  2. TNF Inhibitors predispose to serious infections and malignancy
  3. Prepare for TNF Inhibitor use with infection screening (e.g. Tuberculosis) and Immunizations
    1. See Monoclonal Antibody
  • Adverse Effects
  • Safety
  1. Considered safe in Lactation
  2. Unknown safety in pregnancy (registry exists)
  • References
  1. Hamilton (2020) Tarascon Pocket Pharmacopoeia
  2. (2023) Drugs for Inflammatory Bowel Disease, Med Lett Drug Ther 65: 105-12